Table 2.
Noncancer drug repurposing candidates for HDAC inhibition.
| Drug | Approved for | Epigenetic Target | Cancer Model |
|---|---|---|---|
| Apicidin | Antiprotozoal (not approved) | HDAC3, HDAC4, HDAC8 | Acute Promyelocytic Leukemia [45], Lung Cancer, Colon Cancer, Pancreatic Cancer [46], Cervical Cancer [47] Breast Cancer [48], Endometrial Cancer [49], Ovarian Cancer [50], Oral Squamous Cell Carcinoma [51] |
| Artemisin | Malaria | HDAC1, HDAC2, HDAC6 | Breast Cancer [52] |
| Aspigenin | Natural Compound (not approved) | HDAC class I | Prostate Cancer [53] |
| Carbamazepine | Control of psychomotor or focal seizures | HDAC3, HDAC6, HDAC7 | Breast Cancer [54], Liver Cancer [55], Colon Cancer [56] |
| Ginseng | Natural Compound (not approved) | HDAC | Nonsmall Cell Lung Cancer [57] |
| HC Toxin | Natural Compound (not approved) | HDAC | Breast Cancer [58], Neuroblastoma [59] |
| Psammaplin A | Natural Compound (not approved) | HDAC1, HDAC6, SIRT1 | Lung Cancer [60], Breast Cancer [61,62], Endometrial Cancer [63], Cervical Cancer [64] |
| Sodium Butyrate | Anti-inflammatory | HDAC1 | Gastric Cancer [65], Breast Cancer [66], Prostate Cancer [67] |
| TSA | Antifungal antibiotic | HDAC class I, II and SIRT6 | Breast Cancer [68], Leukemia [69], Esophageal Squamous Carcinoma [70], Prostate Cancer [49,71,72,73], Pancreatic Cancer [74], Colon Cancer [75], Hepatocellular Carcinoma [76] |